Paper Details

  1. Home
  2. Paper Details

Recombinant growth hormone therapy for X-linked hypophosphatemia in children.

Author: RemmingtonTracey, SmithSherie

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.
ReviewAn article that critically examines existing research on a particular topic and summarizes the current state of knowledge in the field.
Systematic ReviewA review that systematically collects, evaluates, and integrates relevant research to answer a specific research question.

Overview

While standard treatment with oral phosphate and calcitriol can help children with X-linked hypophosphatemia, a genetic condition that affects phosphate levels, it doesn't always improve growth or fully restore normal phosphate levels. Some studies suggest that adding growth hormone to standard treatment may improve growth rate and bone density but might worsen their disproportionate height. This review updates previous research on this topic.
Paper Details　
Original Abstract of the Article :
Conventional treatment of X-linked hypophosphatemia with oral phosphate and calcitriol can heal rickets, but it does not always raise serum phosphate concentrations significantly, nor does it always normalize linear growth. Some clinical trials suggest that combining recombinant human growth hormone...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8496964/

データ提供：米国国立医学図書館（NLM）

Growth Hormone Therapy for X-Linked Hypophosphatemia: A Complex Landscape

Treating X-linked hypophosphatemia (XLH) is like navigating a complex desert landscape with shifting sands. This study explores the use of recombinant growth hormone (GH) therapy in combination with conventional treatment for XLH in children. The researchers sought to understand the potential benefits and drawbacks of this approach, as previous studies have shown mixed results.

Some studies suggest that combining GH therapy with conventional treatment can improve growth velocity, phosphate retention, and bone mineral density. However, other studies have suggested that GH therapy may exacerbate the pre-existing disproportionate stature of children with XLH. It's like trying to find the right balance of water and nutrients for different plants in the desert; what works for one may not work for another.

Growth Hormone Therapy: A Balancing Act for XLH

This study highlights the need for careful consideration when using GH therapy in children with XLH. It's like carefully navigating a path through a desert, considering the potential risks and rewards. The study suggests that while GH therapy may offer some benefits, it's important to carefully weigh those benefits against the potential risks, especially regarding disproportionate stature.

Managing XLH: A Multifaceted Approach

This research emphasizes the need for a multifaceted approach to managing XLH in children. It's like understanding the complex ecosystem of a desert and working to create a more balanced environment. By considering all available treatment options, including GH therapy, and carefully monitoring the child's growth and development, healthcare professionals can create a personalized management plan that optimizes outcomes for the child.

Dr.Camel's Conclusion

This study underscores the complexity of managing XLH in children. It's like navigating a desert with hidden dangers and unexpected challenges. GH therapy may offer some benefits, but it's crucial to carefully consider the potential risks and benefits before making a decision. By understanding the nuances of this condition and working closely with healthcare providers, families can navigate the challenges of XLH and ensure the best possible outcomes for their children.

Date :
  1. Date Completed 2021-11-24
  2. Date Revised 2023-02-16
Further Info :

Pubmed ID

34618915

DOI: Digital Object Identifier

PMC8496964

Related Literature

Article Analysis
・Effective treatment of rickets
SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.